Nov 16, 2006 · Zanolimumab (previously referred to as HuMax-CD4) is a fully human monoclonal IgG1k antibody. It is specific for the CD4 antigen expressed ...

Nov 16, 2005 · Zanolimumab, a Fully Human Monoclonal Antibody: Preliminary Results of an Ongoing Clinical Trial in CD4+ Peripheral T-Cell Lymphomas (PTCL).

Nov 16, 2005 · HuMax-CD4 (zanolimumab) is a fully human monoclonal IgG1k antibody, targeting the CD4 molecule on T-cells. ... CD4+ peripheral T-cell lymphoma ( ...

Zanolimumab (previously referred to as HuMax-CD4) is a fully human monoclonal IgG1k antibody. It is specific for the CD4 antigen expressed on a subset of T ...

Nov 16, 2006 · We report initial clinical efficacy and safety results following treatment with 980 mg of zanolimumab in 15 patients diagnosed with biopsy- ...

The development of zanolimumab was recently discontinued by Genmab due to slow patient recruitment into its pivotal study for zanolimumab in CTCL. Siplizumab.

... Zanolimumab was shown to be active and well tolerated in a study of 21 PTCL patients, with an ORR in 24% of patients. 86 Clinical studies of zanolimumab in ...

Jun 23, 2009 · Zanolimumab (HuMax-CD4®; Genmab, Copenhaven, Denmark) is a monoclonal human anti-CD4 antibody and specifically targets Thelper cells as well ...

Zanolimumab, a Fully Human Monoclonal Antibody: Preliminary Results of an Ongoing Clinical Trial in CD4+ Peripheral T-Cell Lymphomas (PTCL). Overview of ...

Zanolimumab, a fully human monoclonal antibody: preliminary results of an ongoing clinical trial in CD4+ peripheral T-cell lymphomas (PTCL) ; 77A · 0006-4971.